Showing results (1-10 of 22) with videos related to
Sort By:
Pageof 3
Frontiers in Neurology|July 30, 2019
Response Predictors in Chronic Migraine: Medication Overuse and Depressive Symptoms Negatively Impact Onabotulinumtoxin-A TreatmentFrancesca Schiano di Cola, Salvatore Caratozzolo, Paolo Liberini, et al.Pain Medicine (Malden, Mass.)|June 28, 2021
Migraine Monitoring in the Time of COVID-19: Triggers and Protectors During a PandemicFrancesca Schiano di Cola, Salvatore Caratozzolo, Marco Di Cesare, et al.Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 20, 2025
Anti-CGRP monoclonal antibodies, migraine and mood disorders: an observational studyMarco Bolchini, Giulia Ceccardi, Francesca Schiano di Cola, et al.European Journal of Neurology|March 1, 2023
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptorFrancesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.European Neurology|December 20, 2022
Migraine Disability and Severity Improvement during Long-Term Treatment with ErenumabMarco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, et al.Frontiers in Neurology|February 6, 2023
Photophobia and migraine outcome during treatment with galcanezumabFrancesca Schiano di Cola, Giulia Ceccardi, Marco Bolchini, et al.Toxins|December 22, 2023
Onabotulinumtoxin-A: Previous Prophylactic Treatment Might Improve Subsequent Anti-CGRP Monoclonal Antibodies Response in Patients with Chronic MigraineGiulia Ceccardi, Francesca Schiano di Cola, Salvatore Caratozzolo, et al.Neurology International|February 22, 2023
Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic MigraineFrancesca Schiano di Cola, Marco Bolchini, Salvatore Caratozzolo, et al.Frontiers in Pain Research (Lausanne, Switzerland)|November 25, 2022
Post COVID-19 vaccination headache: A clinical and epidemiological evaluationGiulia Ceccardi, Francesca Schiano di Cola, Marco Di Cesare, et al.Journal of Neurology|February 24, 2026
Could galcanezumab modulate inflammatory cytokines? A single-centre exploratory studyGiulia Ceccardi, Renata Rao, Francesca Schiano di Cola, et al.Pageof 3